Clinical Trial Details
| Trial ID: | L3444 |
| Source ID: | NCT02562573 |
| Associated Drug: | Pbi4050 |
| Title: | Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes|Metabolic Syndrome |
| Interventions: | DRUG: PBI4050 |
| Outcome Measures: | Primary: Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment, 7 months | Secondary: Change from baseline on waist circumference, 6 months|Change from baseline on biomarkers, % reduction and/or increase of biomarkers, 6 months|Change from baseline on antidiabetic treatment, Treatment discontinued, dosing change, and/or new medication added, 6 months|Change from baseline on triglycerides, 6 months|Change from baseline on BP, 6 months|Change from baseline on HDL-C, 6 Months|Change from baseline on fasting plasma glucose, 6 months |
| Sponsor/Collaborators: | Sponsor: Liminal BioSciences Ltd. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 24 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2015-05 |
| Completion Date: | 2016-11 |
| Results First Posted: | |
| Last Update Posted: | 2017-04-11 |
| Locations: | Edmonton, Alberta, Canada |
| URL: | https://clinicaltrials.gov/show/NCT02562573 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|